129 related articles for article (PubMed ID: 81191)
1. A contribution to immunological tumour diagnostics in urology.
Günther M; Friedrich A; Erdmann T; Jenssen HL; Werner H; Seyfarth M; Köhler H
Int Urol Nephrol; 1978; 10(2):111-5. PubMed ID: 81191
[TBL] [Abstract][Full Text] [Related]
2. [Immunodiagnosis of urologic tumors].
Günther M; Friedrich A; Jenssen HL; Werner H; Köhler H; Seyfarth M; Erdmann T
Z Urol Nephrol; 1977 May; 70(4):225-30. PubMed ID: 331743
[TBL] [Abstract][Full Text] [Related]
3. [A contribution to the early diagnosis and differential diagnosis of bladder neoplasms by means of immunological methods].
Günther M; Friedrich A; Nizze H; Seyfarth M; Jenssen HL; Köhler H; Werner H; Hudemann B; Riedel R; Erdmann T
Z Urol Nephrol; 1978 Feb; 71(2):81-7. PubMed ID: 77116
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. III. Inhibition of leucocyte migration.
Ablin RJ; Marrow C; Guinan PD; Bruns GR; Sadoughi N; John T; Bush IM
Urol Int; 1976; 31(6):444-58. PubMed ID: 1006873
[TBL] [Abstract][Full Text] [Related]
5. Effect of human seminal plasma on tumour-associated immunity in patients with adenocarcinoma of the prostate.
Ablin RJ; Bhatti RA; Bush IM; Guinan PD
J Reprod Immunol; 1980 Feb; 1(5-6):337-45. PubMed ID: 7411523
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice.
Ford TF; Butcher DN; Masters JR; Parkinson MC
Br J Urol; 1985 Feb; 57(1):50-5. PubMed ID: 2578846
[TBL] [Abstract][Full Text] [Related]
7. [The value of histochemical detection of prostate specific antigen].
Hashimoto H; Yachiku S; Nishihara M; Arima S; Tokunaka S; Inada F
Nihon Hinyokika Gakkai Zasshi; 1987 Aug; 78(8):1319-22. PubMed ID: 2449558
[No Abstract] [Full Text] [Related]
8. Cell-mediated immunity in prostatic cancer and its diagnostic relevancy.
Ablin RJ; Guinan PD; Bhatti RA
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):467-71. PubMed ID: 6190657
[TBL] [Abstract][Full Text] [Related]
9. A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer.
Pizza G; De Vinci C; Cuzzocrea D; Menniti D; Aiello E; Maver P; Corrado G; Romagnoli P; Dragoni E; LoConte G; Riolo U; Palareti A; Zucchelli P; Fornarola V; Viza D
Biotherapy; 1996; 9(1-3):123-32. PubMed ID: 8993770
[TBL] [Abstract][Full Text] [Related]
10. Modulatory effects of oestrogen on immunological responsiveness. II. Suppression of tumour-associated immunity in patients with prostatic cancer.
Ablin RJ; Bhatti RA; Guinan PD; Khin W
Clin Exp Immunol; 1979 Oct; 38(1):83-91. PubMed ID: 93529
[TBL] [Abstract][Full Text] [Related]
11. Correlation between tumour stage, tumour grade, and immunocompetence in patients with carcinoma of the bladder and prostate.
Adolphs HD; Steffens L
Eur Urol; 1977; 3(1):23-5. PubMed ID: 837950
[TBL] [Abstract][Full Text] [Related]
12. Immunological studies of patients with tumours of the prostate and bladder (a retrospective analysis).
Romics I; Fehér J; Horváth J
Int Urol Nephrol; 1983; 15(4):339-45. PubMed ID: 6198303
[TBL] [Abstract][Full Text] [Related]
13. Assessment of serum CA 19.9 as a tumour marker in patients with carcinoma of the bladder and prostate.
Abel PD; Cornell C; Buamah PK; Williams G
Br J Urol; 1987 May; 59(5):427-9. PubMed ID: 3474046
[TBL] [Abstract][Full Text] [Related]
14. Transitional cell carcinoma of the bladder. Differences between primary tumour and following relapses.
Pizza G; Viza D; Fini M; Cuzzocrea D; Menniti D; Corrado F
Eur Urol; 1980; 6(1):45-7. PubMed ID: 7353578
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
16. Immunological evaluation in patients with urological cancers.
Martinez-Piñeiro JA; Muntanola P; Hidalgo L
Eur Urol; 1977; 3(3):159-62. PubMed ID: 560302
[TBL] [Abstract][Full Text] [Related]
17. The macrophage electrophoretic mobility assay in patients with renal cell carcinoma.
Malkovský M; Bubeník J; Jakoubková J; Suhajová E; Indrová M; Jandlová T; Símová J
Neoplasma; 1981; 28(2):245-51. PubMed ID: 7254439
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder.
Epstein JI; Kuhajda FP; Lieberman PH
Hum Pathol; 1986 Sep; 17(9):939-42. PubMed ID: 2428729
[TBL] [Abstract][Full Text] [Related]
19. Origin of carcinomas causing bladder neck obstruction demonstrated by immunoperoxidase localisation of specific antigens.
Al Adnani MS
Br J Urol; 1986 Jun; 58(3):283-6. PubMed ID: 3521781
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of serum prostate-specific antigen in urologic cancers.
Takeuchi T; Kuriyama M; Fujihiro S; Fujimoto Y; Okano M; Nishiura T
J Surg Oncol; 1983 Oct; 24(2):157-60. PubMed ID: 6195484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
